Correction to: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy

Zeinab Gharaylou¹ · Abbas Tafakhori² · Elmira Agah^{3,4} · Vajiheh Aghamollaii⁵ · Abbas Kebriaeezadeh⁶ · Mahmoudreza Hadjighassem^{7,8}

Published online: 23 July 2019
© Springer Nature Switzerland AG 2019

Correction to: CNS Drugs (2019) 33:283–291
<https://doi.org/10.1007/s40263-019-00607-5>

The correct name of the co-author should be “Vajiheh Aghamollaii”, and not “Vajihe Aghamollaii” as given in the original publication of the article.

The original article can be found online at <https://doi.org/10.1007/s40263-019-00607-5>.

✉ Mahmoudreza Hadjighassem
mhadjighassem@tums.ac.ir

¹ Department of Neuroscience and Addiction Study, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran

² Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

³ Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁴ NeuroImmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

⁵ Department of Neurology, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran

⁶ Pharmaceutical Management and Economic Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁷ Department of Neuroscience and Addiction Study, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran

⁸ Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran